ALZINOVA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.19 SEK | +12.26% |
|
+3.48% | -60.79% |
| 06-18 | Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study | CI |
| 06-10 | Alzinova AB Announces New External Safety Review for Phase 1b Study | CI |
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâs disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -60.79% | 4.51M | |
| +38.36% | 52.5B | |
| +36.73% | 39.31B | |
| -8.63% | 39.01B | |
| +25.46% | 28.2B | |
| -11.17% | 26.57B | |
| +11.44% | 26.2B | |
| +45.09% | 14.15B | |
| +32.93% | 12.62B | |
| -5.30% | 11.74B |
- Stock Market
- Equities
- ALZ Stock
- News Alzinova AB
- Alzinova Appoints New Chief Medical Officer
